Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab combined with chemoradiotherapy for advanced cervical cancer
ChiCTR2400081017Phase 4Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zimberelimab in Cervical Cancer (CC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2400081017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081017.